Protalix PRX-102: Likely Approval Could Be A Game Changer
May 02, 2022 at 10:02 AM EDT
Protalix's PRX-102 drug stands a good chance of being accepted against Fabry disease, with three P3 trials delivering good results.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|